tcsc1844 Glimepiride

Glimepiride(Amaryl) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.

Target: DPP4

Glimepiride (Hoe 490) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more [1]. glimepiride decreased extracellular Aβ40 and Aβ42 levels. glimepiride may serve as a promising drug for the treatment of AD associated with diabetes [2]. glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning [3].

Clinical indications: Non-insulin dependent diabetes

Toxicity: Severe hypoglycemic reactions with coma; seizure or other neurological impairment.